Same albumin binder as FLGR242. Same 19-day claim. The COA labels a claimed 133 kDa protein a peptide and a MAB. Native Klotho papers do not close the gap.
Growth hormone is not linear. Benefits, risks, and the work required to manage them change with dose, duration, and metabolic context. More is not always better.
MID-35 versus FLGR242: two routes, one evidence standard-
Same target. Almost nothing else in common. One has four mouse papers. The other has a product page, a patent sentence, and certificates that do not settle identity. The gap is the hype.
